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INTRODUCTION
Traumatic brain injury (TBI) affects an estimated 1.7 million people a year. Around 75% of 
these cases are mild. Falls and motor vehicle accidents are among the leading causes for TBI, 
with falls accounting for 60.7% of occurrences in populations 65 years or older1. As the general 
population continues to expand both in age and in size, the risk of falls will increase. This poses 
a problem particularly in light of the pervasive use of anticoagulants and antiplatelet agents for 
this population, both of which increase the bleeding risk.
Anticoagulants and antiplatelet agents are used for a variety of conditions, including deep venous 
thrombosis, atrial fibrillation, pulmonary embolism and coronary artery disease. They are also 
given postoperatively for prosthetic heart valves or stent placement. An estimated 597,689 deaths 
in 2010 were due to cardiovascular disease, with 80% above the age of 652. Stroke caused 129,476 
deaths. The use of anticoagulants and antiplatelet agents for prevention of cardiovascular and 
cerebrovascular events is irrefutable, but little literature has touched on its effects on morbidity and 
mortality in those with traumatic brain injury. 
This article summarizes the current literature 
on the pre-TBI use of anticoagulants and anti-
platelet agents and the associated morbidity 
and mortality.
CASE
A 68-year-old man with a past medical 
history of myocardial infarction 6 months 
ago with stent placement (now on aspirin and 
plavix), HTN, DM, obesity and 40 pack year 
smoking complained of an intense headache 
immediately prior to falling while getting up 
to go to the bathroom. After the fall, his wife 
called the paramedics. Shortly after arriving 
in the emergency department, he became 
unresponsive and was emergently intubated. 
CT scan showed ICH (Figure 1). His ICH score 
upon admission was 4. His coagulation profile 
was normal. His platelets were decreased at 
110,000/uL.
DISCUSSION
A large percentage of the population sustaining 
traumatic brain injury due to falls are also those 
that are likely to be on chronic antiplatelet or 
anticoagulation therapy. The increased risk 
of bleeding with these agents after TBI then 
becomes worrisome, as increased morbidity 
and mortality has been shown to occur with 
any volume of bleeding, with larger volume 
hemorrhages having the worst prognosis.7,8 A 
small number of papers to date have looked 
at warfarin, aspirin or clopidogrel use in mild 
TBI patients and mortality. These studies are 
summarized below and in Table 1.
Warfarin
Warfarin is a vitamin K antagonist, and works 
by inhibiting the enzyme vitamin K epoxide 
reductase, which is responsible for carboxyl-
ating a glutamic acid residue. This is necessary 
for calcium binding, allowing connection to 
phospholipids surfaces to promote clotting. 
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Figure 1
Axial CT scans demonstrating intracerebral hemorrhage.
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irrespective of anticoagulation use also 
seemed to impact mortality, with the majority 
of the deaths occurring in those falling down 
stairs.10 Franko et al. also found a significant 
increase in mortality in patients that were 
anticoagulated, 23.9% versus controls, 4.9%.19 
Pieracci et al. demonstrated increased risk of 
mortality in patients using warfarin before 
ICH compared with patients who did not.20 
Only one study looked at the development 
of ICH after TBI in patients taking warfarin 
and found that it was increased compared to 
controls (57.1% vs. 30.5%).21 In contrast, there 
Use of warfarin has been associated with 
increased risk of intracranial hemorrhage, 
more severe head trauma and increased 
mortality.12 Studies have shown that higher 
INR levels at admission are associated with 
hemorrhage progression and subsequent 
risk of mortality.29-31 The risk of mortality 
in a patient anticoagulated on wafarin with 
an ICH after head injury ranges in the 
literature from 16-80%.13-15 Mina et al. found 
a 33% (4/12) mortality rate in TBI patients 
taking warfarin prior to injury versus 8% 
(3/37) of controls. The severity of the injury, 
Warfarin is cleared by the cytochrome P450 
system in the liver and therefore has the 
potential to interact with a number of drugs. 
Warfarin is indicated for prophylaxis and 
treatment of venous thrombosis, pulmonary 
embolism, atrial fibrillation, post valve 
replacement, stroke or systemic embolization 
after myocardial infarction. It is monitored 
closely with PT and INR due to variable indi-
vidual responses. Therapeutic levels usually 
fall between 2-3 for thromboemolism or atrial 
fibrillation or 2.5-3.5 with mechanical heart 
valves that are in the mitral position.28
Table 1. Summary Of Studies On The Effects Of Anticoagulation Or Antiplatelet Therapy In Patients With Traumatic Brain Injury
Study Therapy
Number of 
Subjects
Mortality Major findings
Wojcik et al., 2001 Warfarin 416 7.5% wafarin 
8.2% control
No difference between mortality, ICU stay, LOS,  
or discharge disposition
Mina et al., 2002 Warfarin 
Aspirin 
Clopidogrel
19 47% aspirin 
33% warfarin 
8% control
Aspirin and warfarin significantly increased mortality
Spektor et al., 2003 Aspirin 110 Not recorded No increased incidence of ICH in patients treated with  
low-dose aspirin
Lavoie et al., 2004 Warfarin 35 40% warfarin 
21% control
Higher frequency of isolate head trauma, more severe head inju-
ries and death
Ohm et al., 2005 Aspirin 
Clopidogrel
90 23% antiplatelet 
8% control
Antiplatelet use in patients with ICH increased mortality
Jones et al., 2006 Clopidogrel 43 7% clopidogrel Increased morbidity and blood transfusion requirement
Franko et al., 2006 Warfarin 159 23.9% 
4.9% control
Mortality with warfarin greater than control
Age a separate predictor of death
Pieracci et al., 2007 Warfarin 1,511 21.9% warfarin 
15.2% control
Increased risk of mortality in patients using warfarin  
before ICH compared with controls
Wong et al., 2008 Clopidogrel 111 14% clopidogrel 
3% asprin
Clopidogrel increases long-term disability and mortality
Ahmed et al., 2009 Warfarin 
Aspirin 
Clopidogrel 
Heparin
29 20% warfarin 
12.5% antiplatelet 
20.6% control
No difference in mortality
Fortuna et al., 2009 Warfarin 
Aspirin 
Clopidogrel
166 6% clopidogrel 
13% aspirin 
17% warfarin 
20% controls
No difference in mortality
Major et al., 2009 Aspirin 
Clopidogrel
287 1.4% aspirin Mortality rate of 21% in patients with ICH on antiplatelet therapy
Bachelani et al., 2011 Aspirin 84 Not recorded Aspirin did not increase risk of ICH progression or poor outcome
Bonville 2011 Warfarin 
Aspirin 
Clopidogrel
271 12.3% aspirin 
9.3% clopidogrel
Warfarin increased mortality, aspirin and clopidogrel did not
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CONCLUSION
Traumatic brain injury is a common cause 
of death in young individuals, but the 
incidence of mortality from TBI is also 
increasing among the elderly. Hemorrhage 
progression has been associated with poor 
outcomes and patients on anticoagulation or 
antiplatelet therapy coming in with TBI need 
to be closely monitored for the first few days. 
With a growing portion of the population on 
anticoagulation and antiplatelet therapy, the 
risk of hemorrhage progression will increase 
and so will mortality. Studies have already 
demonstrated that coagulopathies are associ-
ated with an increased risk of mortality that 
is likely secondary to hemorrhage progres-
sion. A consensus however, still has yet to be 
reached regarding mortality risk and patient 
reported anticoagulant or antiplatelet use in 
traumatic brain injury patients. The benefits 
of stroke or myocardial infarction preven-
tion have to be weighed against the risk of 
hemorrhage and death in those at increased 
risk for traumatic brain injury from a variety 
of causes. Randomized clinical control trials 
need to be carried out in order to accurately 
assess the cause and effect relationship 
between these agents and development of 
intracranial bleeding, progression of bleeding 
and mortality. RCT will also help determine 
the utility of administering FFP or platelets 
for reversal of coagulopathies and the effects 
on morbidity.
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